ACT for Weight-related Experiential Avoidance

August 2, 2022 updated by: Buse Keskindag, Bahcesehir Cyprus University

Acceptance and Commitment Training for Weight-related Experiential Avoidance

This study aimed to investigate whether Acceptance and Commitment Therapy/Training would be helpful to reduce weight-related experiential avoidance among individuals who reported weight concern

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This quasi-experimental study aimed to examine the efficacy of Acceptance and Commitment Therapy/Training (ACT) in reducing weight-related experiential avoidance. Data were collected with a convenience sampling technique. After obtaining ethical approval, participants were invited to participate in the study via advertisements, and online posts. Due to the small sample size, participants who were willing to attend group discussions were included in the experimental group. Participants in the control group did not receive manipulation. All participants were provided with an informed consent form. All participants completed a questionnaire measuring outcomes (weight-related experiential avoidance, general experiential avoidance, eating attitudes, and social physique anxiety) at pre-test, post-test, and follow-up. Participants in the experimental group received ACT training including 6 sessions. The protocol was adapted from Pearson et al. (2012) with their permission. Each session took approximately 80 mins. Several aspects of ACT approach were discussed in the sessions. In session one, ACT approach was introduced. In session two, creative hopelessness was discussed. In session three, control strategies related to weight concern were identified. In session four, mindfulness exercises were completed. In the fifth session, values for meaningful life experience were discussed. In the last, sixth session, the ways to commit to action were discussed. Each session included exercises and homework. At the end of the study, the participants were provided with debrief form.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
32

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Cyprus
      • Nicosia, Cyprus
        • Near East University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Individuals who were 18 years and older
  • Ability to read and understand Turkish

Exclusion Criteria:

  • Individuals who have received mental health intervention over the last one year
  • and those who were diagnosed with an eating disorder were excluded from the analyses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental group
Participants in the experimental group received ACT training in the group setting aiming to reduce weight-related experiential avoidance. This included 6 sessions in total. Each session was completed approximately in 80 mins.
Behavioral: ACT for weight-related experiential avoidance
Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
No Intervention: Control group
Participants in the control group did not receive any manipulation

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in weight-related experiential avoidance
Time Frame: At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)
It was measured by Acceptance and Action Questionnaire for Weight-Related Difficulties-Revised. The scale includes 10 items that are rated on 7 points scale (1 = not true at all - 7 = completely true). Higher scores indicate greater weight related experiential avoidance.
At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in eating attitudes
Time Frame: At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)
Eating attitudes were measured by The Eating Attitudes Test-26. It includes 26 items that are rated on 4 point scale ('3 = Always, 2 = Usually, 1 = Often, 0 = Sometimes, Rarely, and Never'). The last item (26) requires reverse coding. Scores 20 and above indicate dysfunctional eating attitudes.
At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)
Change in general experiential avoidance
Time Frame: At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)
It was measured by Acceptance and Action Questionnaire-II. It includes 7 items that are rated on 7 point scale (1 = never true - 7 = always true). Minimum and maximum scores range between 7 and 49 points. Higher scores indicate greater general experiential avoidance (psychological inflexibility).
At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)
Change in social physique anxiety
Time Frame: At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)
It was measured by The Social Physique Anxiety Scale. The scale includes 12 items are rated on a 5-point scale (1=not at all true to 5=extremely true). Higher scores indicate a higher level of anxiety related to the social physique. Only item 1, 2, 5, 8 and 11 requires reverse coding.
At three time points (pre-intervention [baseline], immediately after the intervention, and at three weeks after the intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bahcesehir Cyprus University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Meryem Karaaziz, PhD, Near East University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Pearson, Adria N., Victoria M. Follette, and Steven C. Hayes.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 4, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 3, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 3, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 30, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 2, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 3, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 3, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 2, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NEU/SS/2022/1208

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings